86 results
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
8 Jan 24
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8:03am
and effectiveness of arimoclomol and any other products and product candidates, and Zevra’s plans, goals and expectations concerning market position, future
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
candidates, Zevra’s commercial infrastructure investments and the impact of the transaction on them, Zevra’s industry, plans, goals and expectations
8-K
6dwhzet
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
425
uyf69n
30 Oct 23
Business combination disclosure
4:42pm
8-K
w0b x4h5m8
30 Oct 23
Other Events
8:25am
8-K
EX-10.1
bzv dyv2adyfe
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
424B3
bip zen3dcg1f9
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
d4ndg8qovrqm3nt66v
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
t860umlg
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
DEFA14A
z1tmxg964z3vs2wx
31 Aug 23
Additional proxy soliciting materials
5:25pm
DEFA14A
EX-99.1
1c59pxhbpd833271rgr
31 Aug 23
Additional proxy soliciting materials
5:25pm
8-K
EX-99.1
fa6c2q31zl
31 Aug 23
Other Events
5:25pm
8-K
ikl04e6a 31ceta17y
31 Aug 23
Other Events
5:25pm
425
jl5h emb3uid
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-99.1
5yrstbq6
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-99.2
oa5svk
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am